Multislice CT reveals previously unseen mets in RCC
MSCT findings and histological feature correlations of pancreatic metastases from clear renal cell carcinoma.
Purpose
The growing use of MSCT in the follow-up of oncologic patients allows early detection of very small pancreatic lesions and particularly of secondary neoplasms.
Material and Methods
We present three cases of pancreatic metastases from clear renal carcinoma confirmed with 64-row MSCT and with histological confirmation of primary RCC and related metastases.
Results
In larger lesions, intravascular contrast administration reveals the differentiation between hypercellular periphery and internal hypodense portions. The hypercellular regions are less vacularized (Figures 1 and 2).
Smaller lesions, seen by more enhancement on arterial phase, were visible as a small spot of extraductal iodine hyperimpregnation and showed a persistence of iodine staining on later scans. Histologically, these demonstrate a prevalence of microvessels and hypercellularity with reduced interstitial anarchy (Figures 3, 4, 5).
Conclusion
It’s probable that the use of recent MSCT scanners, with their superior spatial and temporal resolution, reveals small pancreatic lesions that formerly were missed. In these patients subsequent surgical and medical treatment results in high survival, but makes radiological follow-up extremely important.
Dr. M. Marasà is with the Institute of Radiology at the University of Palermo in Italy; Dr. Dav ì is with the Operative Unit of Vascular and Interventional Radiology at ARNAS-Civico Hospita in Palermo; and Dr. S. Marasà is with the Institute of Pathologic Anatomy at the University of Palermo.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
